Repros Therapeutics Inc (RPRX)

[dewophile]

I hope for Jeff’s sake and yours that I’m wrong

i appreciate that

re selective data disclosure - the irony is that the one issue I would have really liked more clarity on was related to those few patients requiring procedures and the nature/timing of the bleeding pattern once drug is discontinued. to that end the cc actually addressed some of these issues and clarified some of these outstanding issues actually

outside of that I can't think of any possible surprises in the data that could tarnish the approvability of the drug. I just can't